News
Determinants of Resistance to Nivolumab in Advanced Kidney Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, a study was presented that sought to evaluate why advanced renal cell carcinoma (RCC) patients receiving initial treatment with single-agent nivolumab (Opdivo) develop resistance to the PD-1 inhibitor.
In this exclusive MedPage Today video, investigator David A. Braun, MD, PhD, of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut, discusses findings from the genomic and transcriptomic analysis and explains the next steps for the research.
Source: MedPage Today